Press Releases

August 7, 2018

A4250 Phase 3 trial in PFIC underway A4250 granted rare pediatric disease designation, eligible to apply for priority review voucher Management to host conference call and webcast today at 8:30 a.m. EDT BOSTON , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.

July 25, 2018

--- Pediatrician with extensive orphan drug development expertise --- --- Experience with multiple Phase 3 programs and FDA submissions --- BOSTON , July 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile

June 25, 2018

BOSTON , June 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it has been added to the Russell 2000 ® Index as part of the annual reconstitution of the Russell stock

May 29, 2018

BOSTON , May 29, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, is scheduled to present at the Jefferies 2018 Global

May 17, 2018

 First patient enrolled in Phase 3 trial of IBAT inhibitor A4250 in PFIC   Elobixibat in Japan becomes first IBAT inhibitor approved in the world   Management to host conference call and webcast today at 8:30 a.m. EDT  BOSTON , May 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.

May 16, 2018

— Pivotal program in rare and life-threatening pediatric liver disorder underway — — Data intended to provide support for anticipated drug approval applications in US and EU — BOSTON , May 16, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver